StockNews.com Initiates Coverage on BioLineRx (NASDAQ:BLRX)

Stock analysts at StockNews.com assumed coverage on shares of BioLineRx (NASDAQ:BLRX) in a research report issued to clients and investors on Thursday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Separately, HC Wainwright reduced their price target on BioLineRx from $21.00 to $9.00 and set a “buy” rating on the stock in a research report on Monday, November 25th.

BioLineRx Price Performance

Shares of BLRX stock opened at $0.22 on Thursday. The company has a market cap of $17.71 million, a P/E ratio of -1.01 and a beta of 1.39. The company has a quick ratio of 1.37, a current ratio of 1.52 and a debt-to-equity ratio of 2.11. The business has a fifty day simple moving average of $0.34 and a 200 day simple moving average of $0.54. BioLineRx has a twelve month low of $0.19 and a twelve month high of $1.64.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of BLRX. Atria Investments Inc increased its position in shares of BioLineRx by 27.9% during the third quarter. Atria Investments Inc now owns 133,974 shares of the biotechnology company’s stock worth $72,000 after buying an additional 29,193 shares during the period. PVG Asset Management Corp bought a new stake in BioLineRx during the second quarter valued at $70,000. Finally, CVI Holdings LLC acquired a new stake in BioLineRx during the 2nd quarter worth about $462,000. Institutional investors and hedge funds own 1.56% of the company’s stock.

BioLineRx Company Profile

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.